Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021Protocols Published on 2023-12-012024-09-05 Journal: Journal of Virological Methods [Category] update2024, [키워드] COVID-19 Europe SARS-CoV-2 serology Virus neutralisation [DOI] 10.1016/j.jviromet.2023.114825 PMC 바로가기 [Article Type] Protocols
Serological screening in wild ruminants in Germany, 2021/2022: No evidence of SARS-CoV-2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virusArticle Published on 2022-09-012022-11-15 Journal: Transboundary and emerging diseases [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome age antibodies antibody betacoronaviruses bluetongue disease bovine viral diarrhoea collected coronavirus COVID-19 deer disease ELISA Germany human SARS-CoV-2 infectious agent investigated no evidence of occurred pandemic pathogenic Pestivirus positive presence of antibody public health RBD risk ruminant ruminants SARS-CoV-1 SARS-CoV-2 scored Serologically serology Spread susceptible tested the RBD the receptor-binding domain the SARS-CoV-2 virus Virus neutralisation while wildlife [DOI] 10.1111/tbed.14600 PMC 바로가기
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses Exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events장내 미생물 조성은 SARS-CoV-2 백신 면역원성 및 부작용과 관련이 있습니다.Observational Study Published on 2022-06-012022-09-12 Journal: Gut [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] adverse event Anti-inflammatory antibody association Bacteria Bacterial baseline Bifidobacterium BNT162b2 BNT162b2 vaccine carbohydrate collected complement conducted CoronaVac COVID-19 COVID-19 vaccinee COVID-19 vaccines Effectiveness enteric bacterial microflora flagella Gut gut microbiota gut microbiota composition high neutralising antibody Host immune response IgG ELISA immune response Inactivated vaccine individual Intervention Linear Discriminant Analysis marker metabolism metagenomic sequencing Microbiome microbiota modulating mRNA vaccine pathway performed positive correlation Prevotella recipient reduced SARS-CoV-2 SARS-CoV-2 vaccine second dose significantly lower Sinovac spike receptor-binding domain Stool subject the vaccine vaccination Vaccine vaccinee vaccinees Virus neutralisation were measured [DOI] 10.1136/gutjnl-2021-326563 PMC 바로가기 [Article Type] Observational Study
Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients Research Published on 2022-05-192022-10-05 Journal: Communications Medicine [Category] 치료기술, 치료법, [키워드] Adaptive immune response Analysis association blood sample Characteristics chronic illnesses Clinical data collected contribute convalescent COVID-19 patient convalescent patient COVID-19 patient diagnosis of SARS-CoV-2 Health heterogeneity Hong Kong Infection initial laboratory data latent class neutralising antibody occur Older Patient performed Prevent Re-infection Regression model Result risk SARS-CoV-2 SARS-COV-2 infection Seroconversion subject subsequent surveillance data sVNT symptomatic symptomatic patient Symptomatic patients tested the SARS-CoV-2 trajectory Vaccination strategy Variability virus clearance Virus neutralisation were measured [DOI] 10.1038/s43856-022-00119-2 [Article Type] Research
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months6개월 후 백신 단독 또는 SARS-CoV-2 감염 + 백신(하이브리드 면역)에 의해 유도된 항체에 의한 오미크론(B.1.1.529) 변이체의 차선 중화Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Against Anti-RBD IgG antibody B.1.1.529 BBV152 Biotechnology ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation Covaxin Covishield cross-sectional cross-sectional study demonstrated Department exhibited explain foundation four group four groups geometric mean geometric mean titre GMT group groups hybrid Hybrid immunity Immune escape Immunity inactivated India individual Infection limit Live virus Live-virus neutralisation Melinda Gate Melinda Gates moderate natural infection nCoV neutralisation neutralisation assay neutralisation test neutralisation titre Neutralisation titres neutralise neutralising ability omicron Omicron variant outcome Primary outcome quantification Rapid reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant serum Significant Spread subjects tested titre USA vaccinated individual vaccinated individuals vaccination Vaccine variant virus Virus neutralisation [DOI] 10.1016/j.ebiom.2022.103938 PMC 바로가기 [Article Type] Article
Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study애완용 햄스터에서 인간으로 SARS-CoV-2 델타 변이체(AY.127) 전파로 인간 대 인간 전파: 사례 연구Article Published on 2022-03-122022-09-11 Journal: Lancet (London, England) [Category] SARS, 변종, 조류인플루엔자, 치료기술, [키워드] 95% CI analysed animals blood sample Blood samples case study circulating collected Council COVID-19 patient delta variant epidemiological epidemiologically event Evidence evidence of food Genetic Genome Genome sequencing hamster hamsters heterogeneity Hong Kong Human human infections human-to-human transmission humans Illumina infect infected with SARS-CoV-2 Infection Local mammals mice Multiple nasal swab neutralisation test occurred oral oral swabs outbreak phylogenetically PIGS platform positive positive sample Quantitative Quantitative RT-PCR reduction reported resulting RT-PCR RT-qPCR Saliva saliva samples SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 viral SARS-CoV-2-infected hamster SARS-CoV-2-infected hamsters sequence sequenced Sequencing serological Serological tests Serologically Seven subsequent sustained Swab tested Transmission variant viral genome viral genomes virus Virus neutralisation warehouse zoonotic transmission [DOI] 10.1016/S0140-6736(22)00326-9 PMC 바로가기 [Article Type] Article
Humoral immune response after different SARS-CoV-2 vaccination regimens상이한 SARS-COV-2 백신 접종 요법 후 체액 면역 반응Research Article Published on 2022-01-212022-09-01 Journal: BMC Medicine [Category] SARS, 변종, 진단, 치료기술, [키워드] age Alpha anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antibody Response Antigen AstraZeneca avidity AZD1222 B.1.1.7 B.1.1.7 variant B.1.617.2 binding BNT162b2 boost booster vaccination ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration correlation COVID-19 cVNT delta variant examined first vaccination followed by Heterologous homologous humoral immune response Humoral immunity IgG IgG antibodies IgG antibody immune response immunoblot Immunoglobulin Immunoglobulin G individual investigation leads Maturity process Moderna mRNA mRNA vaccine neutralisation test Neutralising Antibodies Occurrence Pfizer/BioNTech Prevalence RBD Receptor binding domain recipient reduction in regimen Result robust S-protein SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 vaccination sera Seroconversion significantly higher significantly lower strength subunit supplementary material sVNT tested the antibody response the RBD the SARS-CoV-2 the vaccine titre titres trimeric vaccination Vaccination schemes Vaccine vaccine dose vaccinee variant Virus neutralisation Virus variants of concern VoC was done was measured was used were measured [DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 20212020년 4월부터 2021년 10월까지 홍콩, 혈액 기증자의 mRNA Comirnaty 및 비활성화된 CoronaVac 백신으로 COVID-19 백신 접종 후 항체 수준 감소Rapid Communication Published on 2022-01-132022-09-12 Journal: Eurosurveillance [Category] SARS, 진단, [키워드] antibody blood donor Blood donors BNT162b2 CoronaVac COVID-19 COVID-19 vaccination COVID-19 vaccination programme cut-off ELISA Hong Kong inactivated Inactivated vaccine median mRNA mRNA vaccine positive remained SARS-CoV-2 second dose sVNT vaccination Vaccine Virus neutralisation [DOI] 10.2807/1560-7917.ES.2022.27.2.2101197 PMC 바로가기 [Article Type] Rapid Communication